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medical costs of elderly Americans are forecasted using the Future Elderly Model 
(FEM) – an established dynamic microsimulation model of health of Americans 
aged over 50. The change in the health and health care costs of obesity due to the 
introduction and widespread use of statins are estimated by introducing a scenario 
in which statins have not been discovered, using well-recognized estimates of the 
health impact of statins. Results: Simulations reveal that the life expectancy of 
50-year-olds with a healthy BMI (18.5-< 25) is 0.92 year longer than it would be in a 
world without statins. Among the obese population, the life expectancy gains due 
to statins are of 1.00 year for type 1 obesity (BMI 30-< 35), 1.05 year for type 2 obesity 
(BMI 35-< 40) and 1.07 year for type 3 obesity (BMI≥ 40). These life expectancy gains 
augment the present value of per capita lifetime health care costs by $15,000 for 
individuals with a healthy BMI, $18,000 for type 1 obesity, $19,100 for type 2 obesity 
and $19,800 for type 3 obesity. About 33% of these costs are shouldered by the 
Medicare program. ConClusions: While the widespread use of statins is beneficial 
for individuals of all weight types, its health impact is highest among the obese 
population. Additional health care costs from statin use are small relative to the 
value of life expectancy gains, and mostly paid for by individuals.
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objeCtives: To assess the health care costs and resource utilization of patients 
with high risk vascular disease (HRVD). Methods: A retrospective cohort study was 
conducted using a large employer-based U.S. administrative claims database. This 
study included patients aged 18 to 64 years who had HRVD (defined as cerebrovas-
cular disease [CVD], coronary artery disease with diabetes [CADD], peripheral artery 
disease [PAD], or history of acute coronary syndrome [ACS] [> = 30days through 365 
days after discharge for ACS]) between 10/01/2008 and 09/30/2009, with minimum 
12-month pre-index and 24-month post-index insurance eligibility. Annual health 
care costs and resource utilization were compared across HRVD patients with 1, 2, 
or 3 affected arterial beds for the first and second year follow-up periods. The com-
parison of mean costs between cohorts was conducted using a generalized linear 
model with log link function and gamma distribution. Results: Of 152,290 patients 
who met the selection criteria, 54.4% were male with mean age 54.5(SD= 7.5). Among 
the identified HRVD patients, during the first/second year, 6.8%/4.3% had ≥ 1 hos-
pitalization event and 27.2%/21.5% had ≥ 1 ER visit. The mean annual number of 
physician office visits was 22/18 for the first and second year respectively. Mean 
total annual health care costs per HRVD patient for the first and second year were 
$19,003/$18,547, of which outpatient costs were $9,698/$8,530, inpatient costs were 
$6,286/$6,220, and pharmacy costs were $3,018/$3,797. HRVD-related costs during 
the first ($8,699) and second year ($7,925) accounted for close to half of the overall 
total health care costs. Mean total annual costs in the first and second year were 
$17,820/$17,501, $28,060/$26,554, and $39,306/$36,513 for patients with 1, 2, and 3 
affected arterial beds (P< 0.001). ConClusions: These results show the high eco-
nomic burden of HRVD and the especially high economic burden associated with 
HRVD patients with multiple affected arterial beds.
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objeCtives: To assess the health care costs and resource utilization of elderly 
patients with high risk vascular disease (HRVD). Methods: A retrospective cohort 
study was conducted using the Truven MarketScan Medicare claims database to 
identify patients > = 65 years, who had HRVD (defined as cerebrovascular disease 
[CVD], coronary artery disease with diabetes [CADD], peripheral artery disease [PAD], 
or history of acute coronary syndrome [ACS] [> = 30days through 365 days after 
discharge for ACS]) between 10/01/2008 and 09/30/2009, with minimum 12-month 
pre-index and 24-month post-index insurance eligibility. Annual health care costs 
and resource utilization were compared across HRVD patients with 1, 2, or 3 affected 
arterial beds for the first- and second-year follow-up periods. The comparison of 
mean costs between cohorts was conducted using a generalized linear model with 
log link function and gamma distribution. Results: The cohort included 203,949 
patients with a mean age of 77.0 years; 52.8% were male. Among the identified HRVD 
patients during the first/second year, 7.3%/6.3% had ≥ 1 hospitalization event and 
27.0%/23.2% had ≥ 1 ER visit. The mean annual number of physician office visits 
was 26/20 for the first and second year respectively. Mean total annual health care 
costs per HRVD patient for the first and second year were $17,899/$17,552, of which 
outpatient costs were $8,911/$6,861, inpatient costs were $5,296/$6,167, and phar-
macy costs were $3,692/$4,525. HRVD-related costs during the first ($7,528) and 
second year ($7,565) accounted for more than 40% of the overall total health care 
costs. Mean total annual costs in the first and second year were $16,794/$16,631, 
$22,116/$21,096, and $26,575/$24,556 for patients with 1, 2, and 3 affected arte-
rial beds (P< 0.001). ConClusions: These results show the high economic burden 
of HRVD and the especially high economic burden associated with elderly HRVD 
patients with multiple affected arterial beds.
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objeCtives: To evaluate the economic burden and health care utilization of general 
cardiovascular disease (CVD) patients in the U.S. Medicare population. Methods: 
A retrospective database analysis was conducted using Medicare data (2008-2010). 
General CVD patients were identified using myocardial infarction (International 
Classification of Disease, 9th Revision, Clinical Modification [ICD-9-CM] codes 410.
xx, 412.xx), unstable angina (411.1x, 411.81, 411.89), ischemic stroke (434.xx, 436.
xx, 437.0x, 437.1x, 438.xx, 997.02), transient ischemic attack (435.xx), heart failure 
(428.xx) and percutaneous coronary intervention (ICD-9 procedure codes 00.66, 
36.09). The first diagnosis date was designated as the index date. One-year con-
tinuous enrollment pre- and post-index date was required. Charlson Comorbidity 
Index (CCI) score and comorbid conditions were examined for the baseline period. 
Prescribed medications were evaluated within 60 days post-diagnosis. Health care 
utilization and costs were measured for the follow-up period. Results: A total 
of 203,865 patients were identified for study (mean age 78.9 years). CVD patients 
were more often female (60.7%), Caucasian (86.0%) and resided in the Southern U.S. 
region. (39.5%). The baseline CCI score was 1.86, and the most frequently diagnosed 
comorbid conditions were diabetes (32.8%), tumor (31.0%) and chronic obstructive 
pulmonary disease (25.6%). Furosemide (13.6%) was most often prescribed within 60 
days after diagnosis, followed by simvastatin (11.4%) and lisinopril (10.6%). Health 
care utilization including Medicare carrier (98.3%), Durable Medical Equipment 
(DME, 43.9%), Home Health Agency (HHA, 25.6%), outpatient visits (80.5%) and inpa-
tient hospital (52.8%), Skilled Nursing Facility (SNF, 17.7%) and hospice admissions 
(8.4%) and prescription claims (54.4%) were observed for the follow-up period. CVD 
patients incurred higher Medicare carrier ($5,679), DME ($534), HHA ($1,506), outpa-
tient ($16,455), inpatient ($12,230), SNF ($3,489), hospice ($822), pharmacy ($1,818) 
and total costs ($42,533). ConClusions: General CVD Medicare patients utilized 
a high percentage of Medicare carrier, outpatient and inpatient utilizations, and 
incurred high health care expenses.
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objeCtives: Cardiovascular (CV) disease significantly contributes to morbidity and 
mortality in chronic obstructive pulmonary disease (COPD) patients; however, the 
economic burden of acute CV events in this population is still unknown. Our objec-
tive was to estimate the direct medical costs associated with the development of 
acute CV events in patients with COPD. Methods: We identified patients with a 
COPD diagnosis (ICD-9 491.x, 492.x, 496.x) between 2005-2010 in the IMS LifeLink 
Health Claims Database. Patients experiencing an incident CV event (MI, ACS, CHF, 
arrhythmia, or stroke) resulting in an ER visit or inpatient admission (case index) 
were matched to up to 3 controls on age, region, gender, year of COPD diagnosis, 
and time between COPD diagnosis and index date. Mean costs (total, inpatient, 
outpatient, and pharmacy) in the 12 months before and after the case index and 
control index were compared, with total costs attributable to the incident CV event 
determined by using a difference in differences regression to adjust for patient 
comorbidities. Results: Among 9,537 case and 26,128 control patients, the aver-
age age was 69.1 years and 51% were male. Hypertension, diabetes, and coronary 
atherosclerosis were the most prevalent comorbidities. Total costs were $27,300 and 
$15,016 (pre-index), and $51,468 and $15,596 (post-index) for cases and controls, 
respectively. Regression analysis resulted in an adjusted difference in differences 
value of $23,601 (p< 0.001). As a percentage of total costs, pharmacy and outpatient 
costs decreased between the pre-index and post-index periods (13% to 8% and 
28% to 22%), while inpatient costs increased (59% to 69%); percentages for control 
patients remained unchanged. ConClusions: The development of acute CV events 
in COPD patients is associated with a large increase in direct medical costs, pre-
dominantly driven by inpatient costs. Interventions aimed at reducing the incidence 
of acute CV events in this population are needed to mitigate overall cost burden.
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objeCtives: This study evaluated the hospital resource utilization associated with 
major adverse cardiovascular events (MACE) in the United States (US) from 2000 to 
2010, overall and by type of event. Of special interest was the rate of death during 
MACE-related hospitalizations. Methods: The Healthcare Cost and Utilization 
Project (HCUP) Nationwide Inpatient Sample (NIS) database was used to estimate 
the annual rates of MACE-related hospitalization for adults aged at least 18 years 
per 100,000 adults as well as per 100,000 adult hospitalizations in the US from 
2000 to 2010 using NIS sampling weights and yearly US Census population infor-
mation. Additionally, average MACE-related per-hospitalization costs (standard-
ized to 2013 USD) and length of stay (LOS) estimates were calculated for each year. 
MACE-related hospitalizations were identified as those with a primary discharge 
diagnosis of acute myocardial infarction (AMI), stroke, or cardiac arrest. Results: 
Rates of MACE-related hospitalization have steadily decreased over time from 685 
to 525 per 100,000 adults and from 4,650 to 3,611 per 100,000 hospitalizations among 
adults in the US from 2000 to 2010. The percentage of MACE-related hospitaliza-
tions resulting in death also decreased from 7.5% in 2000 to 5.3% in 2010. During 
this period, the AMI-related stays accounted for the largest percentage of MACE-
related hospitalizations (51.2%-55.5%), followed by stroke-related (43.9%-48.2%), 
and cardiac arrest-related (0.5%-0.7%) stays. The mean (standard deviation [SD]) 
LOS for MACE-related hospitalizations decreased from 5.4 (6.7) days in 2000 to 4.7 
(5.5) days in 2010. However, the mean (SD) costs per MACE-related hospitalization 
increased from $18,389 ($25,244) in 2000 to $28,629 ($35,008) in 2010. ConClusions: 
Hospitalization and inpatient fatality rates, as well as LOS per hospitalization associ-
ated with MACE have decreased, while costs per MACE-related hospitalization have 
risen in the US between 2000 and 2010. Further research may elucidate the drivers 
of these directionally opposing trends.
